TEC-话题@MedSci

#TEC#

484篇内容 | 2650人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652478, encodeId=176a16524e89f, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=复星医药/BioNTech在中国设立合资公司：mRNA新冠疫苗复必泰年产能达10亿剂，预计7月前被国内批准上市, objectType=article, longId=211050, objectId=500e2110502a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500e2110502a, replyNumber=0, likeNumber=65, createdTime=2021-06-03, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500e2110502a, moduleTitle=复星医药/BioNTech在中国设立合资公司：mRNA新冠疫苗复必泰年产能达10亿剂，预计7月前被国内批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500e2110502a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652464, encodeId=09311652464a6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=有关Nuwiq®在重度血友病A初治患者中免疫原性的NuProtect研究终局数据发表, objectType=article, longId=207549, objectId=bb8520e54947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb8520e54947, replyNumber=0, likeNumber=46, createdTime=2021-04-17, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb8520e54947, moduleTitle=有关Nuwiq®在重度血友病A初治患者中免疫原性的NuProtect研究终局数据发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb8520e54947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652476, encodeId=b14b16524e6cd, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=BioNTech新冠mRNA疫苗或将7月前在中国获批，多款国外疫苗引入疫苗进展缓慢, objectType=article, longId=210641, objectId=38522106413a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38522106413a, replyNumber=0, likeNumber=67, createdTime=2021-11-08, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38522106413a, moduleTitle=BioNTech新冠mRNA疫苗或将7月前在中国获批，多款国外疫苗引入疫苗进展缓慢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38522106413a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652474, encodeId=c58716524e434, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=腾盛博药、Vir Biotechnology和VBI Vaccines宣布启动BRII-835 (VIR-2218)联合BRII-179 (VBI-2601)治疗乙型肝炎的2期临床试验, objectType=article, longId=210372, objectId=3bb22103e2fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bb22103e2fc, replyNumber=0, likeNumber=54, createdTime=2021-05-25, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bb22103e2fc, moduleTitle=腾盛博药、Vir Biotechnology和VBI Vaccines宣布启动BRII-835 (VIR-2218)联合BRII-179 (VBI-2601)治疗乙型肝炎的2期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bb22103e2fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652448, encodeId=e5f916524489d, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=PDS Biotech和Farmacore宣布共同开发基于Versamune的COVID-19疫苗, objectType=article, longId=203272, objectId=9d982032e2c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d982032e2c3, replyNumber=0, likeNumber=107, createdTime=2021-08-10, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d982032e2c3, moduleTitle=PDS Biotech和Farmacore宣布共同开发基于Versamune的COVID-19疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d982032e2c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652451, encodeId=899016524510e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=复发性AML治疗的突破：GoldenBiotech报告了Antroquinonol的试验进展, objectType=article, longId=203852, objectId=f15b203852d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15b203852d0, replyNumber=0, likeNumber=69, createdTime=2021-01-21, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15b203852d0, moduleTitle=复发性AML治疗的突破：GoldenBiotech报告了Antroquinonol的试验进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f15b203852d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652439, encodeId=16de165243937, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=互联互通2019年评级结果与2020新方案发布后，医疗信息化何去何从？【2020CHITEC】, objectType=article, longId=201711, objectId=0c6c201e1157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c6c201e1157, replyNumber=0, likeNumber=51, createdTime=2021-09-02, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c6c201e1157, moduleTitle=互联互通2019年评级结果与2020新方案发布后，医疗信息化何去何从？【2020CHITEC】, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c6c201e1157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652424, encodeId=3d24165242490, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, objectType=article, longId=196192, objectId=ea03196192c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea03196192c4, replyNumber=0, likeNumber=115, createdTime=2021-05-15, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea03196192c4, moduleTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea03196192c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652460, encodeId=3f7016524603c, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=赛诺菲首席执行官：将生产1亿剂辉瑞BioNTech新冠疫苗, objectType=article, longId=206418, objectId=9df620641827, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9df620641827, replyNumber=0, likeNumber=51, createdTime=2021-10-04, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9df620641827, moduleTitle=赛诺菲首席执行官：将生产1亿剂辉瑞BioNTech新冠疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9df620641827)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652455, encodeId=613c1652455d4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, objectType=article, longId=204512, objectId=cc0e204512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc0e204512c6, replyNumber=0, likeNumber=60, createdTime=2021-10-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc0e204512c6, moduleTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc0e204512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652470, encodeId=7a2e16524e0a2, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见, objectType=article, longId=209090, objectId=e891209090ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e891209090ea, replyNumber=0, likeNumber=67, createdTime=2022-01-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e891209090ea, moduleTitle=Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e891209090ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652421, encodeId=bf5b16524213e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, objectType=article, longId=195322, objectId=25f219532272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25f219532272, replyNumber=0, likeNumber=62, createdTime=2020-08-13, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25f219532272, moduleTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25f219532272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652444, encodeId=6f871652444ac, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature：Vir Biotechnology的增强型单克隆抗体可诱导抗病毒感染的CD8+T细胞应答, objectType=article, longId=201934, objectId=9da620193435, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9da620193435, replyNumber=0, likeNumber=49, createdTime=2021-07-23, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9da620193435, moduleTitle=Nature：Vir Biotechnology的增强型单克隆抗体可诱导抗病毒感染的CD8+T细胞应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9da620193435)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652467, encodeId=7619165246ef5, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=MMWR：Pfizer-BioNTech疫苗在疗养院人群中，疗效显著！, objectType=article, longId=208554, objectId=f0e9208554fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0e9208554fe, replyNumber=0, likeNumber=58, createdTime=2021-05-15, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0e9208554fe, moduleTitle=MMWR：Pfizer-BioNTech疫苗在疗养院人群中，疗效显著！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0e9208554fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652443, encodeId=eaa4165244363, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=辉瑞加拿大公司和BioNTech开始向加拿大卫生部提交SARS-CoV-2疫苗候选BNT162b2的滚动申请, objectType=article, longId=201927, objectId=300020192e1c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=300020192e1c, replyNumber=0, likeNumber=72, createdTime=2021-08-29, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=300020192e1c, moduleTitle=辉瑞加拿大公司和BioNTech开始向加拿大卫生部提交SARS-CoV-2疫苗候选BNT162b2的滚动申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=300020192e1c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652468, encodeId=c112165246841, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=因包装问题，香港暂停接种BioNTech疫苗, objectType=article, longId=208956, objectId=9c732089568a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c732089568a, replyNumber=0, likeNumber=46, createdTime=2022-01-15, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c732089568a, moduleTitle=因包装问题，香港暂停接种BioNTech疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c732089568a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652445, encodeId=1f2c1652445c1, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, objectType=article, longId=202660, objectId=e6f9202660eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f9202660eb, replyNumber=0, likeNumber=65, createdTime=2021-01-09, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f9202660eb, moduleTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f9202660eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652430, encodeId=6d4e1652430fe, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol：通过代谢工程为细胞疗法提供一种新型的安全关闭开关, objectType=article, longId=198050, objectId=5ef81980504d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ef81980504d, replyNumber=0, likeNumber=54, createdTime=2020-11-04, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ef81980504d, moduleTitle=Nat Biotechnol：通过代谢工程为细胞疗法提供一种新型的安全关闭开关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ef81980504d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652427, encodeId=3487165242e90, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, objectType=article, longId=197518, objectId=29ba19e518a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ba19e518a8, replyNumber=0, likeNumber=56, createdTime=2020-09-07, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ba19e518a8, moduleTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ba19e518a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652434, encodeId=9946165243454, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol ：深度解读！科学家成功清楚地绘制出人类肠道的微生态系统目录！, objectType=article, longId=198611, objectId=df0a19861118, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df0a19861118, replyNumber=0, likeNumber=0, createdTime=2020-08-09, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df0a19861118, moduleTitle=Nat Biotechnol ：深度解读！科学家成功清楚地绘制出人类肠道的微生态系统目录！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df0a19861118)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TEC

2020-05-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

复星医药/BioNTech在中国设立合资公司：mRNA新冠疫苗复必泰年产能达10亿剂，预计7月前被国内批准上市

2021-06-03

shock_melon (审核中...)

前往app查看评论内容

#TEC#

有关Nuwiq®在重度血友病A初治患者中免疫原性的NuProtect研究终局数据发表

2021-04-17

shock_melon (审核中...)

前往app查看评论内容

#TEC#

BioNTech新冠mRNA疫苗或将7月前在中国获批，多款国外疫苗引入疫苗进展缓慢

2021-11-08

shock_melon (审核中...)

前往app查看评论内容

#TEC#

腾盛博药、Vir Biotechnology和VBI Vaccines宣布启动BRII-835 (VIR-2218)联合BRII-179 (VBI-2601)治疗乙型肝炎的2期临床试验

2021-05-25

shock_melon (审核中...)

前往app查看评论内容

#TEC#

PDS Biotech和Farmacore宣布共同开发基于Versamune的COVID-19疫苗

2021-08-10

医者仁心 (审核中...)

前往app查看评论内容

#TEC#

复发性AML治疗的突破：GoldenBiotech报告了Antroquinonol的试验进展

2021-01-21

shock_melon (审核中...)

前往app查看评论内容

#TEC#

互联互通2019年评级结果与2020新方案发布后，医疗信息化何去何从？【2020CHITEC】

2021-09-02

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功

2021-05-15

shock_melon (审核中...)

前往app查看评论内容

#TEC#

赛诺菲首席执行官：将生产1亿剂辉瑞BioNTech新冠疫苗

2021-10-04

shock_melon (审核中...)

前往app查看评论内容

#TEC#

CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌

2021-10-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见

2022-01-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法

2020-08-13

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature：Vir Biotechnology的增强型单克隆抗体可诱导抗病毒感染的CD8+T细胞应答

2021-07-23

shock_melon (审核中...)

前往app查看评论内容

#TEC#

MMWR：Pfizer-BioNTech疫苗在疗养院人群中，疗效显著！

2021-05-15

shock_melon (审核中...)

前往app查看评论内容

#TEC#

辉瑞加拿大公司和BioNTech开始向加拿大卫生部提交SARS-CoV-2疫苗候选BNT162b2的滚动申请

2021-08-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

因包装问题，香港暂停接种BioNTech疫苗

2022-01-15

shock_melon (审核中...)

前往app查看评论内容

#TEC#

PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者

2021-01-09

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol：通过代谢工程为细胞疗法提供一种新型的安全关闭开关

2020-11-04

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败

2020-09-07

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol ：深度解读！科学家成功清楚地绘制出人类肠道的微生态系统目录！

2020-08-09

科室
- - 订阅+
  - 更多科室
工具
服务